Filing Details

The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 NAMES OF REPORTING PERSONS

 AI Biotechnology LLC

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 (a) ☐  (b) ☐

 SEC USE ONLY:

 CITIZENSHIP OR PLACE OF ORGANIZATION:

 State of Delaware

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 SOLE VOTING POWER:

 0

 SHARED VOTING POWER:

 4,388,560₍₁₎

 SOLE DISPOSITIVE POWER:

 0

 SHARED DISPOSITIVE POWER:

 4,388,560₍₁₎

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

 4,388,560₍₁₎

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

 ☐

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

 9.9%₍₂₎

 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

 OO (Limited Liability Company)

The total number of Class A Ordinary Shares, par value $0.0001 per share (Class A Ordinary Shares), of Zura Bio Limited (the Issuer) reported as beneficially owned includes (i) 4,052,702 Class A Ordinary Shares held directly by AI Biotechnology LLC (AI Biotechnology) and (ii) 335,858 Class A Ordinary Shares issuable upon the partial conversion of pre-funded warrants held directly by AI Biotechnology, which are exercisable at any time or times on or after the date of issuance (the Private Placement Warrants).

The percent of Class A Ordinary Shares reported as beneficially owned is calculated based on the number of Class A Ordinary Shares described in footnote (1) above and, as the denominator, the sum of (i) 43,593,678 Class A Ordinary Shares outstanding, as set forth in the Issuers Quarterly Report on Form 10-Q for the period ended September 30, 2023, filed with the Securities and Exchange Commission (the SEC) on November 13, 2023 and (ii) 335,858 Class A Ordinary Shares issuable upon the partial exercise of Private Placement Warrants held by AI Biotechnology.

 NAMES OF REPORTING PERSONS

 Access Industries Holdings LLC

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 (a) ☐  (b) ☐

 SEC USE ONLY:

 CITIZENSHIP OR PLACE OF ORGANIZATION:

 State of Delaware

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 SOLE VOTING POWER:

 0

 SHARED VOTING POWER:

 4,388,560₍₁₎

 SOLE DISPOSITIVE POWER:

 0

 SHARED DISPOSITIVE POWER:

 4,388,560₍₁₎

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

 4,388,560₍₁₎

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

 ☐

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

 9.9%₍₂₎

 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

 OO (Limited Liability Company)

The total number of Class A Ordinary Shares of the Issuer reported as beneficially owned includes (i) 4,052,702 Class A Ordinary Shares held directly by AI Biotechnology and (ii) 335,858 Class A Ordinary Shares issuable upon the partial conversion of Private Placement Warrants held directly by AI Biotechnology.

The percent of Class A Ordinary Shares reported as beneficially owned is calculated based on the number of Class A Ordinary Shares described in footnote (1) above and, as the denominator, the sum of (i) 43,593,678 Class A Ordinary Shares outstanding, as set forth in the Issuers Quarterly Report on Form 10-Q for the period ended September 30, 2023, filed with the SEC on November 13, 2023 and (ii) 335,858 Class A Ordinary Shares issuable upon the partial exercise of Private Placement Warrants held by AI Biotechnology.

 NAMES OF REPORTING PERSONS

 Access Industries Management, LLC

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 (a) ☐  (b) ☐

 SEC USE ONLY:

 CITIZENSHIP OR PLACE OF ORGANIZATION:

 State of Delaware

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 SOLE VOTING POWER:

 0

 SHARED VOTING POWER:

 4,388,560₍₁₎

 SOLE DISPOSITIVE POWER:

 0

 SHARED DISPOSITIVE POWER:

 4,388,560₍₁₎

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

 4,388,560₍₁₎

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

 ☐

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

 9.9%₍₂₎

 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

 OO (Limited Liability Company)

The total number of Class A Ordinary Shares of the Issuer reported as beneficially owned includes (i) 4,052,702 Class A Ordinary Shares held directly by AI Biotechnology and (ii) 335,858 Class A Ordinary Shares issuable upon the partial conversion of Private Placement Warrants held directly by AI Biotechnology.

The percent of Class A Ordinary Shares reported as beneficially owned is calculated based on the number of Class A Ordinary Shares described in footnote (1) above and, as the denominator, the sum of (i) 43,593,678 Class A Ordinary Shares outstanding, as set forth in the Issuers Quarterly Report on Form 10-Q for the period ended September 30, 2023, filed with the SEC on November 13, 2023 and (ii) 335,858 Class A Ordinary Shares issuable upon the partial exercise of Private Placement Warrants held by AI Biotechnology.

 NAMES OF REPORTING PERSONS

 Len Blavatnik

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

 (a) ☐  (b) ☐

 SEC USE ONLY:

 CITIZENSHIP OR PLACE OF ORGANIZATION:

 United States of America

NUMBER OF

SHARES  BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

 SOLE VOTING POWER:

 0

 SHARED VOTING POWER:

 4,388,560₍₁₎

 SOLE DISPOSITIVE POWER:

 0

 SHARED DISPOSITIVE POWER:

 4,388,560₍₁₎

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

 4,388,560₍₁₎

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

 ☐

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

 9.9%₍₂₎

 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

 IN (Individual)

The total number of Class A Ordinary Shares of the Issuer reported as beneficially owned includes (i) 4,052,702 Class A Ordinary Shares held directly by AI Biotechnology and (ii) 335,858 Class A Ordinary Shares issuable upon the partial conversion of Private Placement Warrants held directly by AI Biotechnology.

The percent of Class A Ordinary Shares reported as beneficially owned is calculated based on the number of Class A Ordinary Shares described in footnote (1) above and, as the denominator, the sum of (i) 43,593,678 Class A Ordinary Shares outstanding, as set forth in the Issuers Quarterly Report on Form 10-Q for the period ended September 30, 2023, filed with the SEC on November 13, 2023 and (ii) 335,858 Class A Ordinary Shares issuable upon the partial exercise of Private Placement Warrants held by AI Biotechnology.

Name of Issuer:

Address of Issuers Principal Executive Offices:

Name of Person Filing:

Address of Principal Business Office or, if none, Residence:

Citizenship:

Title of Class of Securities:

CUSIP Number:

If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

(k)

☐

Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

Ownership.

Amount beneficially owned:

Percent of class:

Number of shares as to which the person has:

Sole power to vote or to direct the vote:

Shared power to vote or to direct the vote:

Sole power to dispose or to direct the disposition:

Shared power to dispose or to direct the disposition:

Ownership of Five Percent or Less of a Class.

Ownership of More than Five Percent on Behalf of Another Person.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the parent Holding Company or Control Person.

Identification and Classification of Members of the Group.

Notice of Dissolution of Group.

Certifications.

The undersigned, by signing his name hereto, executes this Schedule 13G pursuant to the Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.